Publications by V Vanvoorden

Publications by authors named "V Vanvoorden"

J Am Acad Dermatol

September 2023

Bimekizumab, a monoclonal antibody targeting interleukin-17A/F, shows better results than secukinumab in treating psoriasis over one year.
The BE RADIANT trial evaluated its safety and efficacy for 2 years, with participants receiving either bimekizumab or secukinumab followed by an open-label extension of bimekizumab.
Results indicated higher complete skin clearance rates with bimekizumab at Week 48 (74.8% vs 52.8%), and these effects were maintained or improved by Week 96; side effects included nasopharyngitis and urinary tract infections.

Br J Dermatol

May 2023

The study evaluates the long-term effectiveness of bimekizumab (BKZ) for treating moderate-to-severe plaque psoriasis over three years, particularly focusing on maintaining the results achieved at Week 16.
Data from multiple phase III studies and an ongoing open-label extension were used, showing a significant number of patients maintaining high levels of improvement in their psoriasis symptoms throughout the three-year period.
Overall, the results indicate that most patients who responded positively at Week 16 continued to experience substantial benefits and improvements in their quality of life due to ongoing BKZ treatment.

Br J Dermatol

February 2023

Discontinuation of biologic treatments in psoriasis is often due to ineffectiveness or side effects, leading to clinicians and patients considering switching therapies.
The study evaluates the effectiveness and safety of switching to bimekizumab from three other biologics (adalimumab, ustekinumab, and secukinumab) over a period of up to 80 weeks.
Results showed significant improvements in symptoms and quality of life for most patients who switched to bimekizumab, with a high percentage achieving substantial reductions in psoriasis severity, especially among those who initially did not respond well to their previous treatments.

Br J Dermatol

January 2023

1-year data showed bimekizumab's effectiveness exceeds that of adalimumab for treating moderate-to-severe plaque psoriasis, with safe outcomes.
The BE SURE trial tested bimekizumab over 56 weeks, leading into the BE BRIGHT open-label extension for more extended safety and efficacy evaluation.
By week 104, high PASI 90 (91.2% and 89.7%) and PASI 100 (72.3% and 68.1%) responses were seen with bimekizumab, while adalimumab patients also improved significantly after switching to bimekizumab.

Dermatol Ther (Heidelb)

March 2023

Bimekizumab showed significant improvement in treating moderate-to-severe plaque psoriasis over 52 weeks in a phase 3 study, especially in the Japanese patient group.
In the study, patients were assigned to receive either bimekizumab, ustekinumab, or a placebo, with bimekizumab showing superior results at week 16 according to key efficacy measures.
The treatment was found to be well tolerated, with a safety profile consistent with the broader global results.